Remove 2022 Remove Leveraging Remove Liabilities
article thumbnail

Chart of the Month: December 2022

Cobalt

Key Takeaways: The most obvious takeaway from this chart is the consistent upward net asset value (NAV) growth from 2012 to 2022. FactSet does not endorse or recommend any investments and assumes no liability for any consequence relating directly or indirectly to any action or inaction taken based on the information contained in this article.

article thumbnail

Why I'm Not Worried About Verizon's 8%-Yielding Dividend

The Motley Fool

Likewise, any related legal liability would likely take years to materialize, given past litigation for lead-based issues. In 2022, Verizon produced $3.3 Verizon has an excellent bond rating (A-/BBB+/Baa1) backed by a solid leverage ratio of 2.7 (and in early 2022). billion in excess free cash after paying dividends ($10.8

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Time to Pounce: 2 Electrifying Ultra-High-Yield Dividend Stocks That Are Begging to Be Bought in August

The Motley Fool

For example, AT&T's balance sheet has unmistakably improved since content arm WarnerMedia was spun off in April 2022. When coupled with cash payments, AT&T has reduced its net debt from $169 billion on March 31, 2022, to $126.9 There's no doubt that AT&T's dividend is safe with its leverage declining.

article thumbnail

Nikola Stock: Buy, Sell, or Hold?

The Motley Fool

When it went public by merging with a special purpose acquisition company in 2020, it boldly predicted it would deliver 600 BEVs in 2021, 1,200 BEVs in 2022, and 3,500 BEVs in 2023. It finally delivered 131 in 2022 and only 79 in 2023 as it temporarily halted its sales and recalled its trucks after several battery fires. million $38.82

article thumbnail

2024 S&P 500 Bull Market: 2 Unstoppable Growth Stocks to Buy Right Now

The Motley Fool

J&J's overall net sales of $85 billion in 2023 were up 7% from 2022. The medical device business generated net sales of $30 billion, up 12% operationally from 2022, with its Abiomed subsidiary serving as a key driver of this segment's growth. Abiomed is a heart pump specialist acquired by Johnson & Johnson in 2022.

article thumbnail

AbbVie's Recent ImmunoGen Acquisition Looks Brilliant: Here's Why

The Motley Fool

This will equal or eclipse peak Humira sales of $21 billion in 2022. ImmunoGen's flagship drug, Elahere, was approved in late 2022. Here are the assets that add value for AbbVie: Cash: ImmunoGen has $736 million in cash and receivables against just $261 million in total liabilities. billion in 2022 alone on R&D.

article thumbnail

Why DigitalOcean Is a Top Pick for the Next Bull Market

The Motley Fool

Investors feared these factors would significantly dent its revenue growth in 2022, contributing heavily to the company's stock price decline last year. Since the global economy is not out of the woods yet, many of the concerns that hurt the stock in 2022 persist in 2023. This ratio measures a company's financial leverage.

Debt 245